IL312523A - Methods for treating cardiovascular conditions and methods of increasing the efficiency of cardiac metabolism - Google Patents
Methods for treating cardiovascular conditions and methods of increasing the efficiency of cardiac metabolismInfo
- Publication number
- IL312523A IL312523A IL312523A IL31252324A IL312523A IL 312523 A IL312523 A IL 312523A IL 312523 A IL312523 A IL 312523A IL 31252324 A IL31252324 A IL 31252324A IL 312523 A IL312523 A IL 312523A
- Authority
- IL
- Israel
- Prior art keywords
- methods
- increasing
- efficiency
- treating cardiovascular
- cardiovascular conditions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163274389P | 2021-11-01 | 2021-11-01 | |
| PCT/US2022/048401 WO2023076665A1 (en) | 2021-11-01 | 2022-10-31 | Methods for treating cardiovascular conditions and methods of increasing the efficiency of cardiac metabolism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL312523A true IL312523A (en) | 2024-07-01 |
Family
ID=86158627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL312523A IL312523A (en) | 2021-11-01 | 2022-10-31 | Methods for treating cardiovascular conditions and methods of increasing the efficiency of cardiac metabolism |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250235447A1 (https=) |
| EP (1) | EP4426301A4 (https=) |
| JP (1) | JP2024540172A (https=) |
| KR (1) | KR20240095326A (https=) |
| CN (1) | CN118647381A (https=) |
| AU (1) | AU2022376557A1 (https=) |
| CA (1) | CA3236328A1 (https=) |
| IL (1) | IL312523A (https=) |
| WO (1) | WO2023076665A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025054580A1 (en) * | 2023-09-08 | 2025-03-13 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Compositions and methods for increasing myocardial capillary formation, reducing left ventricular hypertrophy and/or reducing ventricular dysfunction |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL283725B2 (en) * | 2017-06-20 | 2024-04-01 | Imbria Pharmaceuticals Inc | Compositions and methods for increasing efficiency of cardiac metabolism |
| TWI683808B (zh) * | 2017-07-18 | 2020-02-01 | 德商菲尼克斯 Ｆｘｒ有限責任公司 | 含有胺或(硫)醯胺之lxr調節劑 |
| EP3976103A4 (en) * | 2019-05-31 | 2023-06-28 | Imbria Pharmaceuticals, Inc. | Methods of altering cardiac remodeling using compounds that promote glucose oxidation |
-
2022
- 2022-10-31 US US18/703,512 patent/US20250235447A1/en active Pending
- 2022-10-31 CN CN202280085857.0A patent/CN118647381A/zh active Pending
- 2022-10-31 AU AU2022376557A patent/AU2022376557A1/en active Pending
- 2022-10-31 KR KR1020247018009A patent/KR20240095326A/ko active Pending
- 2022-10-31 WO PCT/US2022/048401 patent/WO2023076665A1/en not_active Ceased
- 2022-10-31 IL IL312523A patent/IL312523A/en unknown
- 2022-10-31 EP EP22888285.8A patent/EP4426301A4/en active Pending
- 2022-10-31 JP JP2024525619A patent/JP2024540172A/ja active Pending
- 2022-10-31 CA CA3236328A patent/CA3236328A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250235447A1 (en) | 2025-07-24 |
| WO2023076665A1 (en) | 2023-05-04 |
| EP4426301A1 (en) | 2024-09-11 |
| JP2024540172A (ja) | 2024-10-31 |
| AU2022376557A1 (en) | 2024-05-02 |
| CN118647381A (zh) | 2024-09-13 |
| CA3236328A1 (en) | 2023-05-04 |
| KR20240095326A (ko) | 2024-06-25 |
| EP4426301A4 (en) | 2025-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283725A (en) | Compositions and methods for increasing efficiency of cardiac metabolism | |
| CY1127011T1 (el) | Μεθοδος μειωσης του κινδυνου καρδιαγγειακων συμβαντων σε ενα υποκειμενο | |
| EP4025537A4 (en) | Low-energy water treatment | |
| IL272300A (en) | Mavacamten for use in the treatment of hypertrophic cardiomyopathy | |
| EP3555283A4 (en) | ENZYMATIC ENRICHMENT OF N-3 FATTY ACIDS IN THE FORM OF GLYCERIDES | |
| PL3645002T3 (pl) | Sposoby leczenia niewydolności serca za pomocą aktywatorów sarkomerów serca | |
| IL280698A (en) | Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders | |
| DK3842429T3 (da) | Heterocykliske inhibitorer af ERK1 og ERK2 og anvendelse deraf i behandling af cancer | |
| EP3665281A4 (en) | CONDITIONAL SIRNA AND ITS USE IN THE TREATMENT OF CARDIAC HYERTROPHY | |
| IL312523A (en) | Methods for treating cardiovascular conditions and methods of increasing the efficiency of cardiac metabolism | |
| EP4048778A4 (en) | Harnessing the power of microbiota and metabolites for the treatment of cancer | |
| IL284791A (en) | Disease treatment methods with MAGL inhibitors | |
| IL313920A (en) | Treatment of heart and lung disorders | |
| EP3723804A4 (en) | USE OF AN FXIIA INHIBITOR IN THE TREATMENT OF KIDNEY FIBROSIS AND / OR CHRONIC KIDNEY DISEASE | |
| EP4037650A4 (en) | Treatment of alcoholic hepatitis | |
| EP3419614A4 (en) | TREATMENT OF PATIENTS WITH HOMOZYGOT FAMILY HYPERCHOLESTEROLEMIA IN LIPIDICIDING THERAPY | |
| EP4240354A4 (en) | RAF INHIBITOR TO TREAT LOW-GRADE GLIOMAS | |
| PL3445362T3 (pl) | Kompozycja i sposób leczenia zaburzeń metabolicznych | |
| EP4081242C0 (en) | TREATMENT OF ACUTE HEART FAILURE | |
| PL4054582T3 (pl) | Terapeutyczne kombinacje akalabrutynibu i kapiwasertybu w leczeniu nowotworów z komórek b | |
| IL274360A (en) | Methods of treating and protecting against cardiac disease, cardiovascular disease and related conditions and symptoms | |
| EP3946313A4 (en) | PLK1 INHIBITORS AND PSA LEVELS IN PROSTATE CANCER | |
| DK3773744T3 (da) | Sammensætninger og fremgangsmåder til behandling af dominant arvet katekolaminerg polymorf ventrikulær takykardi | |
| EP3952992A4 (en) | METHODS AND MATERIALS FOR GENDER-BASED TREATMENT OF CARDIOVASCULAR DYSFUNCTION | |
| EP3921324A4 (en) | INHIBITORS OF THE ENZYME MENE FORMING ADENYLATE CYCLASE |